In the April issue of MedNous, Dr Steffen Thirstrup shares some thoughts around big data and its essential use in the post-authorisation period of a pharmaceutical.

Digital technology is changing how we collect data for research purposes, and the amount of information collected is growing exponentially. As drug development is focusing on more complex products targeting smaller populations, larger databases to establish the link between the drug and potential unwanted, and in certain cases, extremely rare events are required.

In this article, Dr Steffen Thirstrup explores the past and present approaches to coordinate the collection and analysis of real world data and present updates on the new EU Data Analysis and Real World Interrogation Network (DARWIN EU).


Read More

The Author

Dr Steffen Thirstrup



Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.